Who is sponsoring NCT04703868?

NCT04703868 is sponsored by Yungjin Pharm. Co., Ltd..

What drugs are being tested in NCT04703868?

Interventions in NCT04703868: Rabeprazole Sodium 10mg, Rabeprazole Sodium 20mg.

What condition does NCT04703868 study?

NCT04703868 studies Gastroesophageal Reflux Disease.

Is NCT04703868 still recruiting?

NCT04703868 is currently completed. Last updated 24 January 2024.

Last reviewed 2024-01-24 · How we verify

NCT04703868

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects

Completed Phase 1 Last updated 24 January 2024

What this trial tests

Phase 1 trial testing Rabeprazole Sodium 10mg in Gastroesophageal Reflux Disease in 88 participants. Completed in 14 June 2021.

Timeline

13 January 2021

Primary endpoint
1 June 2021

14 June 2021

Quick facts

Lead sponsor	Yungjin Pharm. Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	88
Start date	13 January 2021
Primary completion	1 June 2021
Estimated completion	14 June 2021
Sites	1 location across South Korea

Drugs / interventions tested

Rabeprazole Sodium 10mg
Rabeprazole Sodium 20mg — full drug profile →

Conditions studied

Gastroesophageal Reflux Disease — all drugs for Gastroesophageal Reflux Disease →

Sponsor

Yungjin Pharm. Co., Ltd. — full company profile →

Who can join

Adults 19 to 55, any sex, with Gastroesophageal Reflux Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole.
Bae S, Kwon J, Lee MH, Yu KS, et al · · 2023 · cited 1× · PMID 36814893 · DOI 10.2147/dddt.s391716

Verify or expand the search:

Other recruiting trials for Gastroesophageal Reflux Disease

Currently open trials in the same condition.

NCT06783751 — Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG) · NA · recruiting
NCT06348420 — Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment · NA · recruiting
NCT06991348 — Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Dise · Phase 4 · recruiting
NCT06732661 — Preserving the Pre-cardial Fat Pad During Sleeve Gastrectomy on Postoperative Gastroesophageal Reflux · NA · active not recruiting
NCT05514769 — Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer · NA · recruiting

Other Yungjin Pharm. Co., Ltd. trials

Trials by the same sponsor.

NCT03261427 — Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administ · Phase 1 · completed
NCT03056209 — Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers · Phase 1 · completed
NCT03275025 — A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis · Phase 2 · completed
NCT02272634 — A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04703868 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yungjin Pharm. Co., Ltd.
Last refreshed: 24 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04703868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing